Eplontersen sodium
依普隆特生钠Ligand-conjugated antisense therapy newly added to the 2026 Commercial Health Insurance Innovative Drug List (#24) for adult hereditary ATTR polyneuropathy.
China Approval (NMPA)
Pending VerificationReimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.
National Reimbursement
Not ListedNot included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).
Commercial Insurance List
Announced · Effective Jan 1, 2027- 2026 List Entry
- #24 · 万诺维
- Validity Period
- 2027-01-01 to 2028-12-31
- MAH / Authorized Entity
- AstraZeneca AB · 阿斯利康(无锡)贸易有限公司
- Listed Indication Scope
- Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.
Approved Products, Dosage Forms & Approval Numbers
0 verified NMPA recordsChange Timeline
- (2027-01-01)Commercial List· Catalog published: Nov 14, 2026
2026 Commercial List · Newly Added (#24)
Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Chinese original: 本品适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。
NHSA · PDF p.4Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14商业健康保险创新药品目录(2026年)Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20